Real-World Study on the Impact of Atopic Dermatitis From a Caregiver Perspective

January 22, 2026 updated by: PeriPharm
This study will address this gap by providing comprehensive data on disease burden from a caregiver perspective in a Canadian population, ultimately supporting improved clinical decision-making and healthcare resource allocation.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis

Description

Inclusion Criteria:

  1. Aged ≥18 years;
  2. Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis;
  3. Able to read and understand French or English;
  4. Willing and able to provide written informed consent.

Exclusion Criteria:

  1. Caregivers whose child has been diagnosed with severe atopic dermatitis ;
  2. Caregivers whose child is currently treated with oral or topical Janus Kinase Inhibitor);
  3. Caregivers whose child is currently participating in a clinical trial for atopic dermatitis;
  4. Other parent or caregiver within the household of the child with atopic dermatitis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Caregiver of child with atopic dermatitis
Caregiver of a child aged ≥2 to ≤11 years with mild to moderate atopic dermatitis
Other: No Intervention: Observational Cohort
No specific intervention is assess in this study. Observational cohort.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To estimate work productivity loss in caregivers of children with mild or moderate atopic dermatitis.
Time Frame: At recruitment
Using the Work Productivity and Activity Impairment questionnaire. This questionnaire provides a quantitative measure of impairment over the last 7 days and includes four metrics: absenteeism (work time missed because of health issues during the past 7 days), presenteeism (impairment while working due to health issues during the past 7 days), overall work productivity loss (combination of absenteeism and presenteeism), and activity impairment.
At recruitment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To estimate family burden of mild to moderate atopic dermatitis in children, as reported by caregivers
Time Frame: At recruitment
The Dermatitis Family Impact (DFI) questionnaire will be administered to caregivers to evaluate the family burden of pediatric atopic dermatitis. The DFI is a validated, 10-item instrument specifically developed for atopic dermatitis, covering domains such as housework, feeding, sleep, leisure activities, time spent shopping, expenditure, physical fatigue, emotional distress, relationships, helping with treatment, with a 7-day recall period. Each item is scored on a 4-point Likert scale ("Not at all = 0" to "Very much = 3"), with higher total scores indicating greater impact
At recruitment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

PeriPharm

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2026

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

July 1, 2026

Study Registration Dates

First Submitted

December 22, 2025

First Submitted That Met QC Criteria

December 22, 2025

First Posted (Actual)

January 7, 2026

Study Record Updates

Last Update Posted (Actual)

January 23, 2026

Last Update Submitted That Met QC Criteria

January 22, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PROxy96AD

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Eczema

Clinical Trials on No Intervention: Observational Cohort

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe